Yang et al. reported that nasal mucosa‐derived EMSCs can upregulate IgG‐2a and IFN‐γ and downregulate IgE, IgG 1, IL‐4, IL‐5, and IL‐10 to balance Th1 and Th2 immune responses in allergic rhinitis.21 This evidence concerns the gene IL5 and allergic rhinitis.